LGI1 Protein — Leucine-Rich Glioma Inactivated 1
Introduction
Lgi1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@senechal2005]
<table> [@yamagata2003]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">LGI1 (Epitempin) Protein</th></tr> [@fukata2006]
<tr><td><strong>Protein Name</strong></td><td>Leucine-rich glioma inactivated 1</td></tr> [@zhou2009]
<tr><td><strong>Alternative Names</strong></td><td>Epitempin, EPTP, ADAM22 ligand</td></tr> [@hijazi2019]
<tr><td><strong>Gene</strong></td><td>[LGI1](/genes/lgi1)</td></tr> [@pennacchio1998]
<tr><td><strong>UniProt ID</strong></td><td>[O75771](https://www.uniprot.org/uniprot/O75771)</td></tr> [@thomas2010]
<tr><td><strong>PDB ID</strong></td><td>2M0M, 2MVH, 3LKK</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>63 kDa (557 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Secreted, synaptic membrane</td></tr>
<tr><td><strong>Protein Family</strong></td><td>LGI family</td></tr>
<tr><td><strong>Tissue Specificity</strong></td><td>Brain (neurons), testis</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>
Overview
LGI1 (Leucine-Rich Glioma Inactivated 1) is a secreted neuronal protein that plays critical roles in synaptic transmission, AMPA receptor trafficking, and neurological disease pathogenesis. Originally identified as a tumor suppressor gene in gliomas, LGI1 is now recognized as a key regulator of synaptic function and is implicated in epilepsy, Alzheimer's disease, and other neurological disorders.
LGI1 is unique among the LGI family proteins as it is the only member known to be secreted and function extracellularly. It acts as a ligand for ADAM22 and ADAM23 receptors, linking presynaptic and postsynaptic compartments.
Structure
LGI1 contains several distinct domains:
- Signal Peptide (1-20 aa): N-terminal secretion signal that targets the protein to the secretory pathway
- Leucine-Rich Repeats (LRR) (30-220 aa): Seven LRR units that mediate protein-protein interactions with ADAM receptors
- Epitempin (EPTP) Domain (320-557 aa): C-terminal domain involved in protein oligomerization and receptor binding
The LRR domain binds to the disintegrin domains of ADAM22/ADAM23, while the EPTP domain mediates LGI1 homodimerization and interaction with other proteins.
Normal Function
LGI1 is essential for normal synaptic function:
Synaptic Transmission
- Binds to ADAM22 and ADAM23 receptors on postsynaptic membranes
- Facilitates synaptic AMPA receptor (AMPAR) trafficking and clustering
- Regulates synaptic strength and plasticity
- Maintains excitatory synaptic transmission
Neuronal Development
- Guides axonal targeting during development
- Regulates dendritic spine morphology
- Supports synapse formation and maturation
Potassium Channel Modulation
- Interacts with Kv1.1 potassium channels
- Modulates neuronal excitability
Mechanism of Action
LGI1 functions as a synaptic organizer:
ADAM22/ADAM23 Signaling
Secreted LGI1 binds to ADAM22/ADAM23 on postsynaptic membranes
This interaction recruits AMPAR to the postsynaptic density
Synaptic AMPAR density increases, enhancing excitatory transmission
The complex stabilizes synaptic structure through interactions with PSD-95Alternative Splicing
LGI1 undergoes alternative splicing, generating multiple isoforms with potentially distinct functions. The major brain isoform contains all functional domains.
Disease Associations
Autosomal Dominant Lateral Temporal Epilepsy (ADLTE)
- Heterozygous LGI1 mutations cause ADLTE (also called Autosomal Dominant Partial Epilepsy with Auditory Features)
- Mutations disrupt protein secretion or receptor binding
- Typically presents with auditory seizures or aphasia
- Second most common genetic epilepsy after SCN1A
Alzheimer's Disease
- LGI1 expression is reduced in AD brains
- May contribute to synaptic dysfunction through AMPAR trafficking deficits
- LGI1 polymorphisms associated with AD risk in some populations
- Potential biomarker for synaptic loss
Amyotrophic Lateral Sclerosis (ALS)
- LGI1 antibodies detected in some ALS patients
- May contribute to excitotoxicity
- Implicated in upper motor neuron dysfunction
Psychiatric Disorders
- LGI1 associations with schizophrenia reported
- May affect [NMDA receptor](/entities/nmda-receptor) function indirectly
Therapeutic Targets
LGI1-related therapies are being explored:
Agonists
- Recombinant LGI1 protein for enhancing synaptic function
- Small molecules promoting LGI1-ADAM22 interaction
- Gene therapy approaches for LGI1 deficiency
Antagonists
- Blocking antibodies for treating LGI1 autoantibody syndromes
- Dominant-negative peptides disrupting LGI1 function
Biomarkers
- CSF LGI1 levels as synaptic marker
- LGI1 autoantibodies in serum/CSF for autoimmune encephalitis
- Recombinant LGI1 protein: For functional studies
- LGI1 knockout mice: For understanding physiological function
- ADAM22/23 knockout mice: For receptor function studies
- LGI1 mutants: For disease mechanism studies
Background
The study of Lgi1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cross-References
- [LGI1 Gene](/genes/lgi1) - Gene page
- [ADAM22 Protein](/proteins/adam22-protein) - Receptor
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
- [AMPA Receptor Signaling](/mechanisms/ampa-receptor-signaling)
- [Epilepsy](/diseases/epilepsy)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Synaptic Dysfunction in Alzheimer's Disease](/synaptic-dysfunction-in-alzheimer's-disease)
See Also
- [Epilepsy Research](/diseases/epilepsy)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Ion Channelopathies](/mechanisms/ion-channelopathies)
- [Neurotransmitter Receptors](/mechanisms/neurotransmitter-receptors)
External Links
- [UniProt: LGI1](https://www.uniprot.org/uniprot/O75771)
- [GeneCards: LGI1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LGI1)
- [OMIM: LGI1](https://www.omim.org/entry/604619)
References
[Feng et al., LGI1 structure and function (2006) (2006)](https://doi.org/10.1016/j.neuron.2006.09.026)
[Senechal et al., LGI1 mutations cause ADLTE (2005) (2005)](https://doi.org/10.1086/491931)
[Yamagata et al., LGI1 as ADAM22 ligand (2003) (2003)](https://doi.org/10.1083/jcb.200305089)
[Fukata et al., LGI1 and epileptic seizures (2006) (2006)](https://doi.org/10.1016/j.neuron.2006.09.030)
[Zhou et al., LGI1 in Alzheimer's disease (2009) (2009)](https://doi.org/10.1016/j.neurobiolaging.2007.10.017)
[Hijazi et al., LGI1 autoantibodies in ALS (2019) (2019)](https://doi.org/10.1212/NXG.0000000000000313)
[Pennacchio et al., LGI1 tumor suppressor (1998) (1998)](https://doi.org/10.1002/j.1460-2075.1998.00711.x)
[Thomas et al., LGI1 and synaptic plasticity (2010) (2010)](https://doi.org/10.1111/j.1471-4159.2010.06858.x)